Doctors urged to prescribe Novo drug only for approved uses

To prevent a shortage of medication, doctors are being urged to only prescribe diabetes and weight loss drugs to approved patient groups, according to the Danish Medicines Agency. This call to action is supported by the European Medicines Agency (EMA) and EU’s authority group on supply security. The concern involves GLP-1 analogues, notably Ozempic by Novo Nordisk, which contains the same substance, semaglutid, found in the weight loss drug Wegovy. High demand has caused supply issues throughout 2023 and 2024, potentially leading to a critical shortage for primary patient groups.